



REPLY TO
ATTENTION OF

DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY
820 CHANDLER STREET
FORT DETRICK MD 21702-5014

August 28, 2019

Assistance Agreements Group

Jian-Hua Mao
Lawrence Berkeley National Laboratory
1488-BioEng and BioMed Science
MailStop: 977
1 Cyclotron Road
Berkeley, CA 94720-8099
jhmao@lbl.gov

RE: BC190820 - "Identification of Genetic Susceptibility to Metastasis Driven by ErbB2"

STATUS: RECOMMENDED FOR FUNDING

Dear Jian-Hua Mao:

Congratulations! On behalf of the Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP), I am pleased to inform you that your Fiscal Year 2019 (FY19) Breast Cancer Research Program (BCRP) Breakthrough Award - Funding Level 2 application submission was recommended for funding. Funding recommendations were made at a second-tier, programmatic review meeting based on program goals and scientific merit. The peer review summary statement for this application and an information paper highlighting the two-tier review process are posted under your electronic Biomedical Research Application Portal (<https://ebrap.org/eBRAP/public/Program.htm>) account.

Funds to be obligated on this award will be available for use for a limited period based on the fiscal year of the funds. That time is considered when establishing the award's period of performance. It is anticipated that this award will be funded with FY19 funds, which will expire for use on September 30, 2025.

Additional documentation is needed to start the award process. Your timely submission of all applicable documents in the appropriate formats will expedite this process and the release of funds. A CDMRP Science Officer will be your scientific and technical point of contact throughout the life of this award and may contact you for further information regarding various aspects of your application. For example, your Science Officer may contact you about animal use and human use documents that may be needed for your project. Together, you will set a target date for the submission of your complete animal use or human use appendix documents. The Surety and Environmental Office will contact you if any Environmental Compliance Assurance documents are necessary.

A Grants/Contract Specialist from the US Army Medical Research Acquisition Activity (USAMRAA) will contact the Business Official (person authorized to conduct negotiations) at your institution to begin award negotiations. All official negotiations of the budget, terms, and conditions of any resulting award will be limited to the Business Official of your institution and the USAMRAA Grants/Contract Specialist.

Your performance on any previous US Army Medical Research and Development Command sponsored awards will be considered during negotiations. As such, you are advised to review your current and past awards to ensure that all required information has been submitted, including all technical reporting and regulatory oversight documents and all financial reports, as this may impact the negotiation and award process.

If you are withdrawing your application, please co-sign a letter of withdrawal with a Business Official at your institution and upload it under the "Required Award Information" tab on eBRAP (<https://eBRAP.org>).

To expedite the award process, please answer the post-submission questions found under the "Required Award Information" tab on eBRAP by September 13, 2019. For additional information, consult the "Guide for Funded Investigators," which can be found in the "Resources and Reference Material" section under the "Funding Opportunities and Forms" tab on eBRAP. Please note the following when supplying the information requested under the above-mentioned tab:

- You and your institution are responsible for ensuring that there is no duplication of the science, budget, or level of effort in separately funded studies in which you were or currently are involved. If you received funding for any portion of this application from another source, or if any portion of the proposed work has already started, please indicate so under this tab.
- Updated details on support for previous funding for the past 5 years, current support, and pending support for yourself and key personnel, including the title of the project, goals, specific aims/tasks, estimated start date and end date, level of effort (percentage or calendar months) in the project, and point of contact at the funding agency. Provide a cover letter signed by a Business Official, certifying that this information is current and accurate, and addresses any scientific or financial overlap.

A copy of this notification is being made available to your institution's Business Official.

Again, congratulations on the recommendation of your application for funding. The CDMRP staff and I look forward to working with you to realize the vision of the BCRP. Please direct any questions to the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

Please note that awards are subject to negotiations and availability of funds.

Sincerely,

Jamie A. Shortall
Grants Officer

cc: Gayle Vaday, Ph.D.
BCRP, Program Manager



Grant Number: 1R01CA184476-01A1
FAIN: R01CA184476

Principal Investigator(s):
Hang Chang, PHD

Project Title: Molecular and Therapeutic Basis of Morphometric Aberrations in Brain Tumors

Garcia, David A
Contracts Officer
1 Cyclotron Road
MailStop: 90R1121
Berkeley, CA 947208099

Award e-mailed to: LBNLAwards@lbl.gov

Period Of Performance:

Budget Period: 05/01/2015 – 04/30/2016

Project Period: 05/01/2015 – 04/30/2020

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$397,189 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA184476. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Silvia Torres
Grants Management Officer
NATIONAL CANCER INSTITUTE

Additional information follows



COMUNICACIÓN DE LA PUBLICACIÓN DE LA RESOLUCIÓN DEFINITIVA DE LA CONVOCATORIA 2017 DE PROYECTOS DE I+D+I CORRESPONDIENTES AL PROGRAMA ESTATAL DE INVESTIGACIÓN, DESARROLLO E INNOVACIÓN ORIENTADA A LOS RETOS DE LA SOCIEDAD, EN EL MARCO DEL PLAN ESTATAL DE INVESTIGACIÓN CIENTÍFICA Y TÉCNICA Y DE INNOVACIÓN 2013-2016.

REFERENCIA: SAF2017-88854-R

ENTIDAD SOLICITANTE: AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)

CENTRO: INSTITUTO DE BIOLOGIA MOLECULAR Y CELULAR DEL CANCER (IBMCC)

TÍTULO: ESTRATEGIAS FARMACOLOGICAS DE PREVENCION DEL CANCER DE MAMA MEDIANTE MODIFICACION DE LA INVOLUCION POSTLACTANCIA

DURACIÓN EN AÑOS: 3

Se ha publicado en la sede electrónica del Ministerio de Ciencia, Innovación y Universidades (<https://sede.micinn.gob.es>) la resolución definitiva de la convocatoria 2017 de ayudas a proyectos de I+D+I correspondientes al Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad.

La ficha económica del proyecto no será enviada a través de Facilit@ puesto que todas las condiciones económicas y de ejecución del mismo se encuentran en la resolución definitiva publicada en la sede.

Contra esta resolución, que pone fin a la vía administrativa, se podrá interponer potestativamente recurso de reposición ante el órgano que la dictó en el plazo de un mes desde el día siguiente al de la notificación, de acuerdo con lo dispuesto en los artículos 123 y 124 de la Ley 39/2015, de 1 de octubre, del Procedimiento Administrativo Común de las Administraciones Públicas.

Sin perjuicio de lo anterior, cabe interponer recurso contencioso-administrativo ante la Sala de lo Contencioso-Administrativo de la Audiencia Nacional, en el plazo de dos meses si la resolución fuera expresa, o de seis meses si no lo fuera, de acuerdo con lo dispuesto en los artículos 11.1.a) y 46 de la Ley 29/1998, de 13 de julio, reguladora de la Jurisdicción Contencioso-Administrativa. No se podrá interponer recurso contencioso administrativo hasta que sea resuelto expresamente o se haya producido la desestimación presunta del recurso de reposición interpuesto.

Agencia Estatal de Investigación



COMUNICACIÓN DE LA PUBLICACIÓN DE LA RESOLUCIÓN DE LA PRESIDENCIA DE LA AGENCIA ESTATAL DE INVESTIGACIÓN, POR LA QUE SE CONCEDEN AYUDAS CORRESPONDIENTES A LA CONVOCATORIA 2020 DE «PROYECTOS DE I+D+i» EN EL MARCO DE LOS PROGRAMAS ESTATALES DE GENERACIÓN DE CONOCIMIENTO Y FORTALECIMIENTO CIENTÍFICO Y TECNOLÓGICO DEL SISTEMA DE I+D+i Y DE I+D+i ORIENTADA A LOS RETOS DE LA SOCIEDAD.

REFERENCIA: PID2020-118527RB-I00

ENTIDAD SOLICITANTE: AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)

CENTRO: INSTITUTO DE BIOLOGIA MOLECULAR Y CELULAR DEL CANCER (IBMCC)

TÍTULO: EVALUACION DE LA PREVENCIÓN DEL CANCER DE MAMA MEDIANTE ANALOGOS DE LA SOMATOSTATINA

DURACIÓN EN AÑOS: 3

Se ha publicado en la página web de la Agencia Estatal de Investigación la resolución por la que se conceden ayudas correspondientes a la convocatoria 2020 de «Proyectos de I+D+i» de los Programas Estatales de Generación de Conocimiento y Fortalecimiento Científico y Tecnológico del Sistema de I+D+i y de I+D+i Orientada a los Retos de la Sociedad.

En el caso de los proyectos aprobados, todas las condiciones económicas y de ejecución de los proyectos se encuentran en la resolución de concesión publicada en la citada sede.

En el caso de los proyectos aprobados tipo JIN, las entidades beneficiarias dispondrán de un plazo de 20 días hábiles a contar desde el día siguiente al de la publicación de la resolución de concesión para formalizar el contrato con el/la investigador/a principal, según lo establecido en los artículos 9.3.a) y 18.3 de la convocatoria, y presentarlo a través de Facilit@, mediante la acción de "Instancia".

La resolución publicada es definitiva en vía administrativa y contra la misma cabe interponer, potestativamente, recurso de reposición ante el mismo órgano que la dictó en el plazo de un mes, de acuerdo con lo dispuesto en los artículos 123 y 124 de la Ley 39/2015, de 1 de octubre, del Procedimiento Administrativo Común de las Administraciones Públicas; o directamente, recurso contencioso-administrativo ante los Juzgados Centrales de lo Contencioso-Administrativo, en el plazo de dos meses, conforme a lo establecido en los artículos 9.1.c) y 46.1 de la Ley 29/1998, de 13 de julio, Reguladora de la Jurisdicción Contencioso-Administrativa.

Agencia Estatal de Investigación